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This case report describes how new tools and technologies can drive a different approach
in the management of arrhythmic patients. An unknown and asymptomatic atrial flutter
was detected by the atrial sensor mounted in a single lead implantable cardioverter
defibrillator. Moreover daily remote monitoring of the device allowed early notification
and prompt clinical reaction. Anticoagulant therapy onset, radiofrequency ablation and
the following anticoagulant therapy removal were driven by the device data
transmissions.
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org/licenses/by-nc-nd/4.0/).Introduction
Different new technologies have become available in the
recent years in the cardiac rhythm disease management.
Atrial sensor in single lead implantable cardioverter defibril-
lator (ICD) and daily remote monitoring are examples of these
innovations. New tools and technologies can drive a different
approach in the management of patients, with efficiency im-
provements and better patient's outcome.ter defibrillator; IEGM, int
e 11, 20090 Vimodrone, M
nik.com (D. Giacopelli).
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A 60-years-old man with ischemic cardiomiopathy
(LVEF ¼ 25%) and two previous coronary artery bypass un-
derwent single-lead ICD (Iforia 5 DX, Biotronik SE & Co. KG,
Berlin, Germany) implantation for primary prevention of
sudden death in April 2014. TheDX ICD is able of atrial sensing
by the presence of a floating dipolemounted 150mm from the
tip and it is equipped with a daily remote monitoring system
(Home Monitoring™, Biotronik SE & Co. KG, Berlin, Germany).
At the time of the implantation the patient had no history of
atrial arrhythmias.racardiac electrogram; HM, Home Monitoring™; AFL, atrial flutter.
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monitoring episode detected” (longer than 8 h) was received:
the message arrived through fax during the night in the cure
centre. The day after we contacted the patient; he was
completely asymptomatic. The supraventricular arrhythmia
had a low ventricular response, the mean heart rate was 83
bpm. We introduced in the patient's therapy a new oral anti-
coagulant drug (apixaban) because he had CHA2DS-VASc
score of 3. In the following days the persistence of the atrial
arrhythymia was confirmed by the intracardiac electrogram
(IEGM) daily sent by the HM (Fig. 1). We had a defined quan-
tification of the arrhythmia with the daily atrial burden value
(percentage of the time in atrial arrhythymia).Fig. 1 e In the first panel the daily HM snapshot showing the a
ventricular annotation; second line, right ventricular farfield sig
line, right ventricular signal; last line, time in seconds. IEGM ¼
burden graph; each black dot represents the daily percentage of
in July 2014. In September 2014 a ablation procedure was perfo
checked in the following days.The patient was scheduled for the ablation procedure
that was performed in September 2014. The synchronized
atrial arrhythmia documented by HM was a typical atrial
flutter (AFL), that was successfully ablated without any
complications. In the following days the maintenance of the
sinus rhythm was monitored: no arrhythmic alerts were
receveid and the atrial burden was permanently 0%, as
shown in Fig. 1.
In October 2014 at the follow up visit, after onemonth from
the ablation, we removed the oral anticoagulant drug in the
patient's therapy; this decision was driven by the fact that any
possible new arrhythmic episodewould be notified in the cure
centre with a HM alert.trial arrhythmia detected. IEGMs: first line, atrial and right
nal; third line, atrial signal from the floating dipole; fourth
intracardiac electrogram. In the second panel the HM atrial
time in atrial flutter (AFL). The onset of the arrhythmia was
rmed, the maintenance of the sinus rhythm were daily
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This case reports an early detection of asymptomatic atrial
arrhythmia with consequent clinical interventions for its
optimal management. This has been possible thanks to the
concomitant utilization of two technologies: the atrial sensing
in a single-lead ICD and the daily remote monitoring of the
device.
An usual single-chamber ICD would not have been able to
detect this arrhythmia due to its low ventricular response,
exactly as the patient had not been able for its asymptomatic
nature. The DX ICDwith floating atrial dipole has been proven
to provide reliable atrial sensing [1] without the need to insert
a second electrode which carries in itself a significant asso-
ciated risk and expense.
There is a substantial incidence of subclinical atrial
tachyarrhythmias which are a leading preventable cause of
recurrent stroke [2]. Therefore we consider crucial having this
information from an implanted device. The data become
meaningful if they are early available for the physician to
prevent arrhythmia-related severe adverse events. Without
remote monitoring any information is available only during
in-hospital follow-up, usually scheduled every 6 or 12months,
significantly delaying any clinical reaction. In this case we had
the opportunity to contact the patient the day after the
arrhythmia occurrence and to have prompt reaction in terms
of drugs therapy modification that may have avoided major
clinical adverse events. Early detection of atrial arrhythmia
and prompt patient management may theoretically prevent
stroke [3,4]; however clinical evidence for stroke risk reduction
by remote monitoring is still awaited. This case is also an
example of HM clinical practice: in our centre there is a
reference nurse for the transmissions who filters the signifi-
cant notifications for the expert physicians. When an organi-
zational model is implemented, the HM has been also
demonstrated to safely reduce healthcare source consump-
tion, in terms of patient visits, time required for patient
follow-up, physician time, costs of patient transport, andhospital incurred costs [5]. Wemanaged this patient remotely;
just one ambulatory visit was performed one month after the
ablation procedure. In this occasion the choice of interrupting
the anticoagulant therapy was taken thanks to the HM pres-
ence. Nowadays telemedicine should be used in the man-
agement of arrhythmic patients [6] and it may guide in some
cases, as in the one here presented, the clinical decisions.Conflict of interest
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